David Sinclair to Test Anti-Aging Drugs in XPrize Competition

David Sinclair, an outstanding gerontologist from Harvard, has announced his plan to test drugs capable of completely rejuvenating the body. The trials will take place as part of the XPrize competition—a platform for innovation that finances projects aimed at solving major problems facing humanity.

A Vision Without Disease

Sinclair has long spoken about transforming medicine. In his view, visiting a doctor over the next two to three decades will not result in prescriptions for disease treatment, but rather prescriptions for anti-aging drugs—as a form of aging prevention. This is not science fiction, but the next wave of pharmaceutical development. The idea is straightforward: if you completely rejuvenate the body, diseases simply will not develop.

How the Longevity XPrize Works

The anti-aging competition attracts the world's best researchers. Its distinctive feature is that funding comes not through traditional academic channels, but through a competitive system.

• The winner will be the one who proves results in practice, not in theory
• Timelines are tight, pressure is high, prizes are substantial
• Teams from different countries and disciplines are involved
• Trials are conducted on volunteers in controlled conditions

Recent Breakthroughs

Sinclair has good reasons for optimism. Recent years have brought real discoveries: senolytic drugs have been identified (which eliminate 'aging' cells), new approaches based on epigenetics and reprogramming have been developed. Companies like Unity Biotechnology and Calico are already testing these drugs on humans with cautious but positive results. NAD-boosters, sirtuins, aging inhibitors—this entire arsenal is ready to move out of laboratories. However, moving from treating individual symptoms of aging to completely rejuvenating the entire body is a different scale. Sinclair understands the complexity and is taking on this challenge through XPrize, where high stakes and accountability for results sharpen the focus.

What This Means

If this experiment succeeds, it will transform the entire longevity market. The field will shift from an area dominated by biohackers to a mainstream sector of the pharmaceutical industry, and for the average person, this means that in a couple of decades, doctor's prescriptions will fundamentally change.